Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINEMAP: Precision Dosing for Linezolid
NCT06444802Phase 3Not yet recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of linezolid in Gram-positive bacterial infection, pneumonia, skin and soft tissue infection (SSTI), sponsored by University Medical Center Hamburg-Eppendorf. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
linezolid
03
Conditions
Gram-positive bacterial infectionpneumoniaskin and soft tissue infection (SSTI)
Beyond the preview
Go deeper on NCT06444802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444802.